Nuclera, a Cambridge, UK-based biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, raised $75M in funding.
The round was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined by British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D. McCreary, Uni Power Group, and Verve Ventures.
The company intends to use the funds for the continued commercialization of its eProtein Discovery™ benchtop system, particularly in the US and across Europe.
Led by CEO Dr Michael Chen, Nuclera offers an eProtein Discovery system that is designed to speed up protein expression and purification in research labs, including those using AI for protein design. The system reduces the time and cost of these processes by automating construct screening, allowing for protein scale-up, and producing milligram amounts of protein in less than 48 hours, compared to the months or years other methods can take.
Using digital microfluidics, protein quality assays, and cell-free protein synthesis on eProtein Discovery cartridges, eProtein Discovery provides rapid access to high-quality proteins at scale, whether using cell-free or cell-based methods.
The system has already been installed at contract research organizations (CROs), biotech and biopharma companies, as well as academic institutes, including University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute.
FinSMEs
16/10/2024